The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes

Advances in Biological Regulation

Volumn 54, Issue 1, 2014, Pages 153-161

  Boultwood, Jacqueline ^a   Dolatshad, Hamid ^a   Varanasi, Satya S ^a   Yip, Bon Ham ^a   Pellagatti, Andrea ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RNA BINDING PROTEIN;

ANIMAL; GENETICS; HUMAN; METABOLISM; MUTATION; MYELODYSPLASTIC SYNDROME; REVIEW; RNA SPLICING; SPLICEOSOME;

ANIMALS; HUMANS; MUTATION; MYELODYSPLASTIC SYNDROMES; RNA SPLICING; RNA-BINDING PROTEINS; SPLICEOSOMES;

EID: 84893395823     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2013.09.005     Document Type: Review

References (42)

1. Abdel-Wahab O., Adli M., LaFave L.M., Gao J., Hricik T., Shih A.H., et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012, 22:180-193.
2. Abdel-Wahab O., Levine R. The spliceosome as an indicted conspirator in myeloid malignancies. Cancer Cell 2011, 20:420-423.
3. Bejar R., Levine R., Ebert B.L. Unraveling the molecular pathophysiology of myelodysplastic syndromes. JClin Oncol 2011, 29:504-515.
4. Bejar R., Stevenson K.E., Caughey B.A., Abdel-Wahab O., Steensma D.P., Galili N., et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. JClin Oncol 2012, 30:3376-3382.
5. Boultwood J., Pellagatti A., McKenzie A.N., Wainscoat J.S. Advances in the 5q- syndrome. Blood 2010, 116:5803-5811.
6. Boultwood J., Yip B.H., Vuppusetty C., Pellagatti A., Wainscoat J.S. Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies. Adv Biol Regul 2013, 53:8-17.
7. Corey S.J., Minden M.D., Barber D.L., Kantarjian H., Wang J.C., Schimmer A.D. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007, 7:118-129.
8. Corrionero A., Minana B., Valcarcel J. Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. Genes Dev 2011, 25:445-459.
9. Damm F., Kosmider O., Gelsi-Boyer V., Renneville A., Carbuccia N., Hidalgo-Curtis C., et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012, 119:3211-3218.
10. Ebert B.L., Pretz J., Bosco J., Chang C.Y., Tamayo P., Galili N., et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008, 451:335-339.
11. Edmond V., Moysan E., Khochbin S., Matthias P., Brambilla C., Brambilla E., et al. Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J 2011, 30:510-523.
12. Graubert T., Walter M.J. Genetics of myelodysplastic syndromes: new insights. Hematology Am Soc Hematol Educ Program 2011, 2011:543-549.
13. Graubert T.A., Shen D., Ding L., Okeyo-Owuor T., Lunn C.L., Shao J., et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2012, 44:53-57.
14. Greenberg P.L. The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features. JNatl Compr Canc Netw 2013, 11:877-885.
15. Hoskins A.A., Moore M.J. The spliceosome: a flexible, reversible macromolecular machine. Trends Biochem Sci 2012, 37:179-188.
16. Kulasekararaj A.G., Mohamedali A.M., Mufti G.J. Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes. Br J Haematol 2013, 162:587-605.
17. Lardelli R.M., Thompson J.X., Yates J.R., Stevens S.W. Release of SF3 from the intron branch point activates the first step of pre-mRNA splicing. RNA 2010, 16:516-528.
18. Lindsley R.C., Ebert B.L. Molecular pathophysiology of myelodysplastic syndromes. Annu Rev Pathol 2013, 8:21-47.
19. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. NEngl J Med 2006, 355:1456-1465.
20. Makishima H., Visconte V., Sakaguchi H., Jankowska A.M., Abu Kar S., Jerez A., et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012, 119:3203-3210.
21. Malcovati L., Papaemmanuil E., Bowen D.T., Boultwood J., Della Porta M.G., Pascutto C., et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011, 118:6239-6246.
22. Maquat L.E. Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat Rev Mol Cell Biol 2004, 5:89-99.
23. Mian S.A., Smith A.E., Kulasekararaj A.G., Kizilors A., Mohamedali A.M., Lea N.C., et al. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. Haematologica 2013, 98:1058-1066.
24. Ogawa S. Splicing factor mutations in myelodysplasia. Int J Hematol 2012, 96:438-442.
25. Osman S., Albert B.J., Wang Y., Li M., Czaicki N.L., Koide K. Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464. Chemistry 2011, 17:895-904.
26. Pan Q., Shai O., Lee L.J., Frey B.J., Blencowe B.J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008, 40:1413-1415.
27. Papaemmanuil E., Cazzola M., Boultwood J., Malcovati L., Vyas P., Bowen D., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. NEngl J Med 2011, 365:1384-1395.
28. Papaemmanuil E., Gerstung M., Malcovati L., Tauro S., Gundem G., Van Loo P., et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013, 10.1182/blood-2013-08-518886.
29. Patnaik M.M., Lasho T.L., Hodnefield J.M., Knudson R.A., Ketterling R.P., Garcia-Manero G., et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012, 119:569-572.
30. Pellagatti A., Jadersten M., Forsblom A.M., Cattan H., Christensson B., Emanuelsson E.K., et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A 2007, 104:11406-11411.
31. Przychodzen B., Jerez A., Guinta K., Sekeres M.A., Padgett R., Maciejewski J.P., et al. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood 2013, 122:999-1006.
32. Quesada V., Conde L., Villamor N., Ordonez G.R., Jares P., Bassaganyas L., et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012, 44:47-52.
33. Raza A., Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer 2012, 12:849-859.
34. Schellenberg M.J., Dul E.L., MacMillan A.M. Structural model of the p14/SF3b155. branch duplex complex. RNA 2011, 17:155-165.
35. Shih A.H., Levine R.L. Molecular biology of myelodysplastic syndromes. Semin Oncol 2011, 38:613-620.
36. Thol F., Kade S., Schlarmann C., Loffeld P., Morgan M., Krauter J., et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012, 119:3578-3584.
37. Visconte V., Makishima H., Maciejewski J.P., Tiu R.V. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia 2012, 26:2447-2454.
38. Visconte V., Rogers H.J., Singh J., Barnard J., Bupathi M., Traina F., et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 2012, 120:3173-3186.
39. Webb T.R., Joyner A.S., Potter P.M. The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. Drug Discov Today 2013, 18:43-49.
40. Xiao R., Sun Y., Ding J.H., Lin S., Rose D.W., Rosenfeld M.G., et al. Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis. Mol Cell Biol 2007, 27:5393-5402.
41. Yoshida K., Sanada M., Shiraishi Y., Nowak D., Nagata Y., Yamamoto R., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478:64-69.
42. Zhang S.J., Rampal R., Manshouri T., Patel J., Mensah N., Kayserian A., et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012, 119:4480-4485.